Formulation compatibility of myristyl nicotinate with drugs used to treat dermatological conditions involving an impaired skin barrier.
A number of dermatology conditions including skin photodamage, atopic dermatitis, and rosacea involve skin barrier impairment and first line therapies for these conditions including retinoids and steroids further impair skin barrier function. We have evaluated the compatibility of myristyl nicotinate, an agent that enhances skin barrier function, with drugs used to treat conditions where skin barrier impairment is present including photodamage (retinoic acid), atopic dermatitis (hydrocortisone, triamcinolone acetonide), rosacea (metronidazole), and seborrheic dermatitis (ketoconazole). Myristyl nicotinate was found to be compatible with each of the drugs examined when formulated together and also was shown to be photocompatible with retinoic acid. Our results suggest that the combination of myristyl nicotinate with these drugs is a feasible therapeutic development strategy.
Department of Pharmaceutical Technology, Faculty of Pharmacy Jordan University of Science and Technology, Irbid-Jordan.
Bassam M
BM
Tashtoush
Hyuntae
H
Kim
Elaine L
EL
Jacobson
Myron K
MK
Jacobson
D002626:Chemistry, Pharmaceutical; D003879:Dermatologic Agents / Q000737:chemistry* / Q000493:pharmacokinetics; D006801:Humans; D006854:Hydrocortisone / Q000737:chemistry; D007654:Ketoconazole / Q000737:chemistry; D008795:Metronidazole / Q000737:chemistry; D009525:Niacin / Q000031:analogs & derivatives* / Q000737:chemistry; D012867:Skin / Q000378:metabolism*; D012871:Skin Diseases / Q000188:drug therapy; D014212:Tretinoin / Q000737:chemistry; D014222:Triamcinolone Acetonide / Q000737:chemistry
D003879:Dermatologic Agents; D008795:Metronidazole; D009525:Niacin; D014212:Tretinoin; C509652:myristyl nicotinate; D014222:Triamcinolone Acetonide; D007654:Ketoconazole; D006854:Hydrocortisone